Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II bevacizumab dose-escalation in malignant effusion
2006-003230-15Phase 2Completed
- Sponsor
- University Hospital Bonn, Department of Internal Medicine I
- Start
- Oct 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in malignant pleural effusion (MPE), pleural effusion and malignant ascites, sponsored by University Hospital Bonn, Department of Internal Medicine I. Primary endpoint: Centesis-free interval (CFI). Started Oct 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
malignant pleural effusion (MPE)pleural effusionmalignant ascites
Beyond the preview
Go deeper on 2006-003230-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003230-15.